Supplemental material

Supplemental Table 1. The association of mean inflammatory sNfL level calculated from at least two measurements and fGd+ with MRI

atrophy and clinical measures at the 10-year follow-up, corrected for age, sex, DMT use, eTIV (MRI volume measures), BL T2LC and BL

Gd+LC.

			Mean infla	mmatory sNfL lev	vel		fGd+				Full model	
MRI/clinical measure	Ν	В	Std. B	95% conf. interval	p- value*	В	Std. B	95% conf. interval	p- value*	R ² adj.	p-value	
Total GM volume	35				NS				NS			
Total WM volume	35				NS				NS			
Total subcortical GM volume	35	-96.27	-0.397	-175.064, -17.482	0.036				NS	0.132	0.018	
Thalamus volume	35				NS				NS			
Mean Cth	35	-0.002	-0.433	-0.004, -0.001	0.036				NS	0.163	0.009	
logLesion volume ^b	39				NS				NS			
logLesion count ^b	39	0.004	0.508	0.002, 0.007	0.008				NS	0.238	0.001	
EDSS≥4 ^c	45				NS				NS			
logT25FW ^b	43				NS				NS			
logChange in T25FW ^b	41				NS				NS			
logD9-HPT ^b	43				NS				NS			
logChange in D9-HPT ^b	41				NS	-0.554	-0.406	-0.928, -0.180	0.010	0.285	0.004	

Supplemental Table 1. Model 1: The association of inflammatory sNfL level and fGd+ with MRI atrophy and clinical measures at the 10-year follow-up,

logND9-HPT ^b	42				NS				NS		
logChange in ND9-HPT ^b	41	-0.454	-0.320	-0.803, -0.105	0.012	-0.005	-0.405	-0.009, -0.001	0.035	0.367	0.001
PASAT	42				NS				NS		
Change in PASAT	40				NS				NS		
Oral SDMT	42				NS				NS		

^{*a*} Non-significant covariates removed from final model by backward elimination.

^b Dependent variable log transformed due to non-normality (log-linear transformation).

^c Analysed by logistic regression.

*Adjusted p-values after controlling the False discovery rate (FDR) for multiple hypothesis testing.

Abbreviations: sNfL=serum neurofilament light chain, eTIV=estimated total intracranial volume, DMT=disease modifying therapy,

BL=baseline, Gd+=gadolinium-enhancing, LC=lesion count, fGd+=fraction of MRI scans with new Gadolinium-enhancing lesion, N=number,

B=beta, Std=standardised, GM=grey matter, WM=white matter, NS=not significant, Cth=cortical thickness, EDSS=expanded disability status

scale, T25FW=timed 25-foot walk, D9-HPT=dominant hand 9-hole peg test, ND9-HPT=non-dominant hand 9-hole peg test, PASAT=paced

auditory serial addition test, SDMT=symbol digit modalities test.

Supplemental Table 2. The association of mean non-inflammatory sNfL level calculated from at least two measurements with MRI atrophy and clinical measures at the 10-year follow-up, corrected for age, sex, DMT use, eTIV (MRI volume measures), BL T2LC and BL Gd+LC.

Supplemental Table 2. Model 2: The association of mean non-inflammatory sNfL level with MRI atrophy and clinical measures at the 10-year follow-up, corrected for age, sex, DMT use, eTIV, BL T2LC and BL Gd+LC^a.

		Mean	non-inflam	matory sNfL level	Full model			
MRI/ clinical measure	Ν	В	Std. B	95% conf. interval	p-value*	R^2 adj.	p-value	
Total GM volume	59				NS			
Total WM volume	59				NS			
Total deep GM volume	59				NS			
Thalamus volume	59				NS			
Mean Cth	59				NS			
logLesion volume ^b	60				NS			
Lesion count	60				NS			
EDSS≥4 ^c	67				NS			
logT25FW ^b	64				NS			
logChange in T25FW ^b	62				NS			
logD9-HPT ^b	63				NS			
logChange D9- HPT ^b	61				NS			
logND9-HPT ^b	62				NS			
Change in ND9- HPT	60				NS			
PASAT	65				NS			
Change in PASAT	63				NS			
Oral SDMT	60	0.446	0.389	0.168, 0.724	0.002	0.321	< 0.001	

^{*a}* Non-significant covariates removed from final model by backward elimination.</sup>

^b Dependent variable log transformed due to non-normality (log-linear transformation).

^c Analysed by logistic regression.

*Adjusted p-values after controlling the False discovery rate (FDR) for multiple hypothesis

testing.

Abbreviations: sNfL=serum neurofilament light chain, eTIV=estimated total intracranial volume, DMT=disease modifying therapy, BL=baseline, Gd+=gadolinium-enhancing, LC=lesion count, N=number, B=beta, Std=standardised, GM=grey matter, WM=white matter, NS=not significant, Cth=cortical thickness, EDSS=expanded disability status scale, T25FW=timed 25-foot walk, D9-HPT=dominant hand 9-hole peg test, ND9-HPT=nondominant hand 9-hole peg test, PASAT=paced auditory serial addition test, SDMT=symbol digit modalities test. Supplemental table 3. The association of mean inflammatory sNfL level calculated from at least three measurements and fGd+ with MRI

atrophy and clinical measures at the 10-year follow-up, corrected for age, sex, DMT use, eTIV (MRI volume measures), BL T2LC, BL Gd+LC

and MRI atrophy measurements obtained at month 24.

			Mean inflan			fGd+	Full model			
MRI measure	Ν	В	Std. B	95% conf. interval	p-value* B	Std. B	95% conf. interval	p-value*	R ² adj.	p-value
Total GM volume	19				NS			NS		
Total WM volume	19				NS			NS		
Total deep GM volume	19				NS			NS		
Thalamus volume	19				NS			NS		
Mean Cth	19				NS			NS		

^{*a}</sup> Non-significant covariates removed from final model by backward elimination.*</sup>

*Adjusted p-values after controlling the False discovery rate (FDR) for multiple hypothesis testing.

Abbreviations: sNfL=serum neurofilament light chain, eTIV=estimated total intracranial volume, DMT=disease modifying therapy,

BL=*baseline*, *Gd*+=*gadolinium*-*enhancing*, *LC*=*lesion count*, *fGd*+=*fraction of MRI scans with new Gadolinium*-*enhancing lesion*, *N*=*number*,

B=beta, *Std=standardised*, *GM=grey matter*, *WM=white matter*, *NS=not significant*, *Cth=cortical thickness*.

Supplemental Table 4. Multiple linear regression with cortical thickness of the left and right precentral gyrus as dependent variables, mean inflammatory sNfL level, D9-HPT, change in D9-HPT, ND9-HPT and change in ND9-HPT are included as independent variables in separate models, all corrected for age, sex, DMT use, BL T2LC, BL Gd+LC and fGd+.

Supplemental Table 4. The association of mean inflammatory sNfL level, D9-HPT and ND9-HPT with mean cortical thickness of the precentral gyri at the 10-year follow-up, corrected for age, sex, DMT use, BL T2LC, BL Gd+LC and fGd+^a.

Cortical thickness left	precen	tral gyrus					
Independent variable	Ν	В	Std. B	95% conf. interval	p-value*	R^2 adj.	p-value
Mean inflammatory sNfL level	25	-0.006	-0.498	-0.010, -0.001	0.015	0.216	0.011
D9-HPT	66	-0.011	-0.426	-0.018, -0.005	0.001	0.169	<0.001
Change in D9-HPT	62				NS		
ND9-HPT	64				NS		
Change in ND9-HPT	62				NS		
Cortical thickness rig	ht prec	entral gyrus	6				
Mean inflammatory sNfL level	25	-0.006	-0.488	-0.010, -0.001	0.013	0.206	0.013
D9-HPT	66	-0.010	-0.410	-0.016,	0.001	0.276	< 0.001

sNfL level				-0.001			
D9-HPT	66	-0.010	-0.410	-0.016,	0.001	0.276	< 0.001
				-0.005			
Change in D9-HPT	62				NS		
ND9-HPT	64				NS		
Change in ND9-HPT	62				NS		

^{*a*} Non-significant covariates removed from final model by backward elimination.

*Adjusted p-values after controlling the False discovery rate (FDR) for multiple hypothesis

testing.

Abbreviations: sNfL=serum neurofilament light, BL=baseline, Gd+=gadolinium-enhancing,

LC=lesion count, fGd+=fraction of MRI scans with new Gadolinium-enhancing lesion, D9-

HPT=dominant hand 9-hole peg test, ND9-HPT=non-dominant hand 9-hole peg test,

 $DMT = disease \ modifying \ therapy, \ N = number, \ B = beta, \ Std = standardised, \ conf = confidence, \ and \ and$

adj=adjusted.